---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-109753"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2024-09-27T23:59:59+00:00"
generated_at: "2026-05-31T01:12:46.423707+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Olema targets IND for KAT6 drug OP-3136 in Q4 2024; Phase 1/2 starts 2025

## Summary
- Non-clinical data for OP-3136 (KAT6 inhibitor) to be presented at ENA symposium Oct 23-25, 2024.
- IND submission for OP-3136 anticipated in Q4 2024.
- Phase 1/2 clinical study for OP-3136 expected to begin in 2025.
- Potential Phase 3 trial OPERA-02 (palazestrant + ribociclib) initiation planned for 2025.

## SEC filing metadata
- accession: 0000950170-24-109753
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2024-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000095017024109753/0000950170-24-109753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000095017024109753/olma-20240927.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-109753
- JSON: https://secwatch.observer/filing/0000950170-24-109753.json
- Plain text: https://secwatch.observer/filing/0000950170-24-109753.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.